What Are Renal Lesions? Causes, Detection, and Management

A renal lesion is any abnormal area of tissue in the kidney, ranging from a harmless fluid-filled cyst to a cancerous tumor. Most renal lesions are discovered by accident when a person undergoes imaging for an unrelated reason, and the vast majority turn out to be benign. Still, the word “lesion” on a radiology report can send anyone into a panic, so understanding what these findings actually mean, how doctors evaluate them, and when treatment is needed goes a long way toward putting the situation in perspective.

How Renal Lesions Are Usually Found

The rise of CT scans, MRIs, and ultrasounds for everything from back pain to gallstones has dramatically increased the number of kidney abnormalities caught on film. These so-called “incidentalomas” show up in people who have no kidney symptoms at all and were being imaged for something else entirely.¹ In one large study, roughly one in seven patients who had an unenhanced CT scan turned out to have at least one renal mass.² That figure surprises most people, but it reflects how common small, benign kidney cysts really are, especially as we age.

What Causes Renal Lesions

The causes depend heavily on the type of lesion. Simple cysts, by far the most common, appear to develop when tiny outpouchings on the kidney’s microscopic tubes gradually enlarge over time. Current thinking traces these cysts back to small bulges (diverticula) on the distal tubules of the kidney. As the tubular walls weaken with age, these pockets can detach, fill with fluid, and slowly grow into the cysts that show up on imaging.³ Older research also pointed to localized obstruction of the tubules as a contributing factor.⁴ This explains why simple cysts are rare in children but extremely common in older adults.

Solid renal lesions have a wider range of causes. Angiomyolipomas, the most frequently encountered benign solid kidney tumors, are made up of fat, smooth muscle, and blood vessels. These can occur on their own or as part of a genetic condition called tuberous sclerosis. Oncocytomas are another benign solid tumor that can mimic cancer on imaging. On the malignant side, renal cell carcinoma is the most common kidney cancer in adults, and it comes in several subtypes with different behaviors and prognoses.

Some renal lesions have a hereditary basis. Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cystic kidney disease and causes numerous cysts to grow in both kidneys over a person’s lifetime. Other hereditary conditions that produce kidney cysts or tumors include tuberous sclerosis, Von Hippel-Lindau syndrome, and several rarer syndromes.⁵ A family history of kidney cysts or kidney cancer appearing at a young age should prompt a conversation with a doctor about genetic evaluation.

Cystic Versus Solid Lesions

The first thing a radiologist determines when a kidney lesion is spotted is whether it is cystic (fluid-filled) or solid. This distinction matters enormously because the two categories carry very different risks.

Simple cysts are thin-walled sacs of clear fluid. They are almost always harmless. They do not turn into cancer, and unless they grow large enough to cause pain or press on nearby structures, they are left alone. Complex cysts are a different story. These have features that raise suspicion: internal walls (septations), thickened or calcified borders, solid components, or areas that light up after contrast dye is injected. The more complex the cyst looks, the higher the chance it harbors cancer.

Solid masses can be benign or malignant. A mass containing visible fat on a CT scan is usually an angiomyolipoma and can often be diagnosed without a biopsy. But many solid masses lack fat and share overlapping imaging features, making it difficult to tell a benign oncocytoma from a small renal cell carcinoma without tissue sampling or surgery.

How the Bosniak Classification Works

For cystic kidney masses, doctors rely on a grading system called the Bosniak classification, which has been the standard for over three decades.⁶ It sorts cysts into categories based on their imaging appearance and assigns a rough probability of malignancy to each.

Category I: A simple cyst with thin walls, no septations, and no enhancement. Malignancy risk around 3%.
Category II: Minimally complex, with a few thin septations or tiny calcifications. Risk about 6%.
Category IIF: Slightly more complex features that warrant follow-up imaging (“F” stands for follow-up). Risk roughly 7%.
Category III: Indeterminate cysts with thickened or irregular walls, measurable enhancement, or multiple thick septations. About half turn out to be malignant.
Category IV: Clearly malignant-appearing, with large enhancing solid components. Over 90% are cancerous.

These pooled malignancy rates come from a large meta-analysis of CT-based studies.⁷ The classification was updated in 2019 to address some long-standing limitations, including how to handle lesions seen on MRI and how to reduce disagreement between radiologists reading the same scan.⁸

Imaging Tools for Evaluating Renal Lesions

Ultrasound is often the first imaging study that spots a kidney lesion. It is widely available, uses no radiation, and does an excellent job identifying simple cysts. When a mass clearly meets all the criteria for a simple cyst on ultrasound, no further workup is needed.⁹ Problems arise with masses that do not look entirely simple or that are solid, because standard ultrasound has limited ability to characterize these further.

CT scanning with intravenous contrast is the workhorse for kidney mass evaluation. The key question a contrast-enhanced CT answers is whether a lesion “enhances,” meaning it takes up contrast dye and appears brighter after injection. Enhancement signals that a mass has its own blood supply, which distinguishes a solid tumor or complex cyst from a simple, benign cyst. Radiologists look for an increase in density (measured in Hounsfield units) between the pre-contrast and post-contrast images. However, certain cancer subtypes, particularly papillary renal cell carcinoma, can enhance very little and sometimes fall below the usual detection thresholds, potentially being mistaken for benign cysts.¹⁰

MRI adds another layer of information. It excels at soft-tissue contrast and can use specialized techniques like chemical shift imaging and diffusion-weighted imaging to help differentiate tumor types.¹¹ In one study, multi-parametric MRI achieved an overall accuracy of about 93% for distinguishing malignant from benign kidney masses.¹² MRI is also used to apply the “clear cell likelihood score,” a tool that helps identify clear cell renal cell carcinoma, the most common and aggressive subtype of kidney cancer, without requiring a biopsy.¹³

When a Biopsy Is Considered

Despite advances in imaging, some kidney masses remain “indeterminate,” meaning the scans cannot confidently say whether a lesion is benign or malignant. In these situations, a percutaneous (through-the-skin) biopsy may be recommended. A needle is guided into the mass using CT or ultrasound, and a tiny tissue sample is removed for examination under a microscope.

Biopsy accuracy is generally good for confirming malignancy. One study found that biopsy results matched the final surgical pathology for malignancy in 100% of cases and matched the specific tumor type in about 85%.¹⁴ Biopsies are also generally safe, with minor complications occurring in fewer than one in ten patients. However, diagnostic yield drops for smaller masses. Biopsies of masses between 3 and 4 cm tend to provide a diagnosis more reliably than those smaller than 3 cm, and a meaningful percentage of biopsies come back “nondiagnostic,” meaning the tissue sample was not sufficient to reach a conclusion.¹⁵ In one series, about 16% of biopsy specimens were nondiagnostic.¹⁶

Biopsy results can change the treatment plan. If a mass that looked suspicious on imaging turns out to be benign, a patient may be spared surgery entirely. On the other hand, identifying the specific cancer subtype can guide the choice between surgery, ablation, or surveillance.

The Oncocytoma Problem

One of the most frustrating challenges in kidney lesion management is telling oncocytomas apart from chromophobe renal cell carcinomas. These two tumor types look strikingly similar on routine imaging and even under the microscope. Oncocytomas are completely benign and never spread, while chromophobe renal cell carcinoma is a true cancer, albeit usually a slow-growing one. Because of the difficulty distinguishing them, many patients with oncocytomas have undergone unnecessary surgery.

Researchers have been working on ways to solve this problem without a knife. MRI-based approaches measuring how quickly a lesion enhances after contrast can help separate the two: oncocytomas tend to show a higher peak in the early phase of enhancement compared to chromophobe cancers.¹⁷ Radiomics, which uses computer algorithms to extract subtle patterns from CT images that the human eye cannot detect, has also shown promise.¹⁸ On the molecular front, a recent study identified a small panel of gene expression and DNA methylation markers that could distinguish aggressive chromophobe cancers from indolent oncocytic tumors, with validation accuracy above 0.88.¹⁹ These tools are not yet standard practice, but they point toward a future where fewer people undergo surgery for a tumor that would never have harmed them.

Management Options

What happens after a renal lesion is identified depends on its size, its imaging characteristics, the patient’s age and overall health, and whether a biopsy has been performed. The main management paths fall into three broad categories: surveillance, ablation, and surgery.

Active Surveillance

For small, low-risk masses, especially in older patients or those with significant health problems, watching and waiting is a legitimate strategy. Most small renal masses grow slowly. A study of elderly patients on active surveillance found that growth rates for small masses were modest, and age by itself (as a continuous variable) was not linked to faster growth.²⁰ Active surveillance typically involves periodic imaging, often every six to twelve months initially, with the interval lengthening if the mass stays stable. If a mass begins growing faster or changes its appearance, the plan can shift to treatment.

Ablation

For small tumors (generally 4 cm or less) that warrant treatment but where surgery is not ideal, ablation is an option. The two most established techniques are cryoablation (freezing the tumor) and radiofrequency ablation (heating it). A meta-analysis found that cryoablation had lower rates of local tumor regrowth than radiofrequency ablation, with about 5% of cryoablated lesions showing local progression versus roughly 13% for radiofrequency.²¹ Microwave ablation is a newer entrant; a 12-year single-center comparison of microwave and cryoablation found no significant differences in local recurrence, cancer-free survival, or overall survival between the two.²² Ablation is typically performed percutaneously under image guidance, which means a shorter recovery time compared to surgery.

Surgery

When a renal mass is large, clearly malignant, or in a location that makes ablation impractical, surgery is the standard treatment. The two main operations are partial nephrectomy (removing the tumor while preserving the rest of the kidney) and radical nephrectomy (removing the entire kidney). Modern guidelines favor partial nephrectomy whenever technically feasible, because keeping more kidney tissue translates into better long-term kidney function. In one study, the average kidney filtration rate a year after surgery was substantially higher in the partial group than the radical group.²³

Partial nephrectomy also appears to carry a survival advantage, at least in the first several years after surgery. Observational data show consistently higher survival in the partial group, with the difference driven not by cancer deaths but by other causes of death, suggesting that preserving kidney function protects overall health.²⁴ The one randomized trial that directly compared the two operations, however, muddied the picture somewhat: it actually found slightly worse overall survival in the partial nephrectomy group, though the evidence quality was low and the finding has been debated extensively.²⁵ Despite that trial, the weight of observational evidence and kidney-function data has kept partial nephrectomy as the preferred approach for masses that are amenable to it.

What Happens After Surgery for Kidney Cancer

For localized renal cell carcinoma, surgery is considered curative, but recurrence remains a real concern. Depending on the stage at diagnosis, survival rates range from roughly 53% to 85%.²⁶ For people whose cancer has spread or who are at high risk of recurrence, immunotherapy and targeted therapy have become established treatments in the metastatic setting. Research into whether these drugs can reduce recurrence when given after surgery for localized disease is ongoing and is one of the most active areas in kidney cancer research.

Benign Tumors That Still Need Attention

Not all benign renal lesions can simply be ignored. Angiomyolipomas, while noncancerous, have a tendency to bleed spontaneously, especially when they grow larger than about 4 cm. A ruptured angiomyolipoma can cause massive bleeding into the space behind the kidney, a condition known as Wunderlich syndrome. Angiomyolipomas and renal cell carcinomas together account for about 60-65% of all Wunderlich syndrome cases.²⁷ Pregnancy increases the risk further, as angiomyolipomas can grow faster under hormonal influence and are more prone to rupture during that time.²⁸ For this reason, larger angiomyolipomas are often treated preemptively with selective embolization, a procedure that cuts off the tumor’s blood supply, or with partial nephrectomy.

Kidney Lesions in Children

Renal lesions in children are a different clinical landscape. Kidney tumors make up roughly 3-11% of all pediatric tumors worldwide, and the overwhelming majority of these are Wilms tumors, accounting for about 80-90% of pediatric kidney cancers.²⁹ Wilms tumor is treated very differently from adult kidney cancer, usually with a combination of chemotherapy and surgery, and outcomes are generally favorable when caught early. Other pediatric kidney tumors include clear cell sarcoma of the kidney, mesoblastic nephroma, and malignant rhabdoid tumor, each of which has a distinct biology and treatment approach. Simple cysts, so common in adults, are rare in children and warrant more thorough investigation when found, because they may signal an underlying genetic condition.

Artificial Intelligence in Lesion Assessment

AI and machine learning are being tested as tools to help radiologists classify kidney lesions more accurately and consistently. One multicenter study evaluated a deep learning system designed to predict malignancy risk in cystic renal lesions and reported very high accuracy, with an area under the curve above 0.97 in validation and above 0.99 in testing.³⁰ These results are impressive on paper, though translating them into real-world clinical workflows is still in progress. One concern is that patients are increasingly turning to AI chatbots for reassurance after receiving a report about an incidental kidney finding, and the accuracy and safety of AI-generated patient-facing advice in emotionally sensitive situations like a possible cancer diagnosis remain uncertain.³¹

Contrast Dye and Kidney Safety

Since CT scans with contrast dye are the backbone of kidney lesion evaluation, a reasonable question is whether the contrast itself can harm the kidneys. Contrast-induced nephropathy, a temporary drop in kidney function after receiving iodinated contrast, is rare in people with healthy kidneys. The risk climbs, however, in people who already have reduced kidney function, diabetes, or advanced age, potentially reaching as high as 25% in high-risk groups.³² The condition is self-limiting in most cases, but it can occasionally lead to lasting kidney damage or the need for dialysis.³³ This is why doctors check kidney function with a blood test before ordering a contrast-enhanced scan, and why MRI (which uses a different type of contrast agent) or contrast-enhanced ultrasound may be preferred for patients whose kidneys are already compromised. Newer biomarkers for early detection of contrast-related kidney injury are under investigation, which could eventually allow doctors to intervene sooner in at-risk patients.³⁴